• EAGLE-1: Oral Gepotidacin for Gonorrhoea

  2026-09-09

  The phase 3 EAGLE-1 trial found that two oral doses of gepotidacin were non-inferior to ceftriaxone plus azithromycin for microbiological clearance of uncomplicated urogenital gonorrhoea. Its main innovation is clinical validation of a first-in-class oral antibacterial that inhibits bacterial DNA replication, providing a potential alternative treatment strategy as resistance reduces the usefulness of established therapies.

• A40926 Workflows for Cell Wall Antibiotic Research

  2026-09-08

  A40926 combines a defined cell-wall target with useful activity against MRSA, other Gram-positive pathogens, and Neisseria gonorrhoeae. This practical guide connects concentration-response testing, glycopeptide derivative work, and fermentation optimization to reproducible bench decisions.

• Bestatin (Ubenimex): Mechanism and Assay Use

  2026-09-08

  Bestatin, also called Ubenimex, is a research inhibitor of aminopeptidase B, leucine aminopeptidase, aminopeptidase N, and related zinc aminopeptidases. Its selective biochemical profile supports aminopeptidase activity measurement and multidrug resistance research, but assay conditions and cellular effects must be interpreted independently.

• Trypsin BA5744: From Proteolysis to Fusion Assays

  2026-09-07

  Trypsin is more than a routine protein digestion enzyme: its sequence-selective cleavage can become a deliberate variable in cell, inflammation, and membrane-fusion experiments. This article connects BA5744 handling with modern assay design and the membrane-localized nanotherapy concepts reported by Yu et al.

• QPRT Drives Breast Cancer Invasion via MLC Phosphorylation

  2026-09-07

  Liu et al. identify quinolinate phosphoribosyltransferase (QPRT) as a pro-invasive factor in breast cancer and connect its activity to purinergic signaling, Rho/ROCK, PLC, MLCK, and myosin light chain phosphorylation. The study combines tumor expression analysis, genetic perturbation, motility assays, and pharmacologic pathway dissection to position QPRT–MLCK signaling as a mechanistic framework for studying breast cancer invasion.

• Phosphotungstic Acid Negative Stain Solution: EM Guide

  2026-09-05

  Phosphotungstic Acid Negative Stain Solution (2%) provides a practical electron microscopy readout for particle morphology and sample quality. This guide connects coronavirus glycan biology with rigorous image interpretation while clarifying what negative stain electron microscopy can—and cannot—prove.

• A 83-01: From TGF-β Mechanism to Translation

  2026-09-04

  A mechanistic and strategic guide to using A 83-01 as an ALK-5 inhibitor in fibrosis, EMT, organoid, and translational research. The article connects TGF-β/Smad biology with LMCD1-driven corneal myofibroblast differentiation and outlines assay, selectivity, and decision-making considerations beyond a typical product page.

• Z-VAD-FMK: Mapping Caspase-Dependent Cell Death

  2026-09-04

  Z-VAD-FMK is a cell-permeable pan-caspase inhibitor for testing whether cell death depends on caspase activation. This guide connects apoptosis inhibition with RIP1-centered inflammatory death research and shows how to design more discriminating assays.

• Streptozotocin Workflows for Diabetes Research

  2026-09-03

  Build reproducible hyperglycemia models with Streptozotocin while linking β-cell injury to diabetes-related complications. This practical guide connects STZ model design with painful diabetic neuropathy assays, including TBK1–microglia pyroptosis readouts and troubleshooting.

• HOXC8 Suppresses Pyroptosis in Lung Tumorigenesis

  2026-09-03

  The reference study identifies HOXC8 as a transcriptional brake on caspase-1 expression in non-small cell lung cancer, thereby limiting gasdermin D-dependent pyroptosis. Its central contribution is the discovery of an ASC-independent mechanism in which HOXC8 recruits HDAC1/2 to the CASP1 promoter, linking oncogenic transcriptional control with inflammatory cell death.

• Novobiocin: From Mechanism to Evidence

  2026-09-02

  Novobiocin is an aminocoumarin antibiotic with unusually broad value across bacterial, parasitic, and viral models. This evidence-centered guide shows how to distinguish target engagement from downstream phenotypes and design more interpretable antimicrobial assays.

• Omeprazole A2845: Acid Secretion Workflow Guide

  2026-09-02

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for biochemical and functional studies of gastric acid secretion, including antiulcer activity study workflows. It is intended only for scientific research and should not be used for diagnostic, medical, or therapeutic applications.

• CX-4945 (Silmitasertib) in Lung Cancer Research

  2026-09-01

  CX-4945 (Silmitasertib) gives cancer researchers a time-controlled way to connect CK2 signaling with apoptosis, cell-cycle behavior, ECE-1c stability, and cisplatin resistance. This practical workflow translates recent NSCLC findings into pathway, phenotypic, and resistance assays while emphasizing solvent control and model-specific validation.

• PRDX6–GPX4 Axis in Ferroptosis Resistance

  2026-09-01

  Hu et al. identify PRDX6 as a dual regulator of ferroptosis resistance: it removes peroxide-containing phospholipids and promotes GPX4 relocation to membranes through a redox-sensitive interaction. The findings connect PRDX6 inhibition with stronger ferroptosis-inducing therapy and tumor suppression in liver and ovarian cancer models.

• Tofacitinib Repairs GM-CSF–Reprogrammed RA Macrophages

  2026-08-31

  The reference study identifies a GM-CSF-driven macrophage endotype in rheumatoid arthritis that couples inflammatory activation to oxidative stress and mitochondrial fragmentation. It shows that Tofacitinib broadly reverses this state by reducing GM-CSFRα-associated signaling, inhibiting STAT5 activity, and restoring regulatory and metabolic features more effectively than the metabolic interventions tested.

8129 records 5/542 page Previous Next 12345 下5页 Last page